Trials / Completed
CompletedNCT02832180
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, 2-cycle, multiple-dose, single-sequence study in women of child-bearing potential. The primary objective is to assess the effect of BMS-986142 on the pharmacokinetics (PK) of Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OC containing EE and NET | |
| DRUG | BMS-986142 |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2016-07-14
- Last updated
- 2016-12-26
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02832180. Inclusion in this directory is not an endorsement.